Drug intelligence / Profile preview

rCERP-HER2

Development stage: Preclinical
Lead developer: Hauul Bio
Modality: Cell Therapies
Administration: Intravenous

Overview

rCERP-HER2 is a preclinical-stage cell therapy developed by Hauul Bio using its proprietary rCERP (recombinant Cell-Engaging Receptor Protein) platform. The therapy is designed to target HER2-expressing malignancies, specifically breast cancer. The rCERP platform involves engineering cells to express receptor proteins that facilitate engagement with specific tumor antigens, thereby promoting immune-mediated cytotoxicity. In preclinical studies, rCERP-HER2 has demonstrated activity in breast cancer models and has been evaluated alongside the HER2-targeted antibody-drug conjugate Kadcyla (trastuzumab emtansine) as an external reference to benchmark its efficacy.

Other names: rCERP-HER2 cell therapyrCERP-HER-2 cell therapyrCERP-HER 2 cell therapy

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on rCERP-HER2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rCERP-HER2.

Explore the full profile